Abstract PS3-08-16: Real-world patterns of chemotherapy use in premenopausal women with node-negative early-stage HR+/HER2− breast cancer and intermediate genomic risk

Clinical Cancer Research 2026

View at publisher
Authors: Ismail Ajjawi, M. Wong, Wei Wei, T. Park, J. Du, M. Rozenblit, Sarah E. Schellhorn, Adriana Matutino Kahn, Nicole A. Casasanta, Eric P. Winer, M. Lustberg
DOI: 10.1158/1557-3265.sabcs25-ps3-08-16
Cited by: 0

Abstract

Abstract Background: The optimal use of adjuvant chemotherapy in premenopausal women with early-stage hormone receptor-positive (HR+), HER2-negative (HER2−), node-negative breast cancer and intermediate Oncotype DX recurrence scores remains an area of clinical uncertainty. While prospective trials have provided clearer guidance for postmenopausal women, real-world treatment patterns and decision-making processes among premenopausal patients remain less well defined. Methods:We performed a retrospective analysis using the National Cancer Database (NCDB) to identify premenopausal women (

Fields of Study & Subjects

Breast Cancer Treatment Studies BRCA gene mutations in cancer Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS3–08
Publication date
17 February 2026
Language
EN